SciELO - Scientific Electronic Library Online

 
vol.18 issue4Emphysematous pyelonephitis: Report of two cases and review. author indexsubject indexarticles search
Home Pagealphabetic serial listing  

Services on Demand

Journal

Article

Indicators

  • Have no cited articlesCited by SciELO

Related links

  • Have no similar articlesSimilars in SciELO

Share


Revista Medica Herediana

Print version ISSN 1018-130XOn-line version ISSN 1729-214X

Abstract

PINTO VALDIVIA, Miguel Eduardo et al. Graves disease: report of two HIV cases of Inmune Reconstitution Syndrome following highly active antiretroviral therapy.. Rev Med Hered [online]. 2007, vol.18, n.4, pp.218-221. ISSN 1018-130X.

We report two cases of Graves’ disease after immune reconstitution following highly active antiretroviral therapy (HAART). We reviewed and abstracted the patients’ records and also conducted a review of the pertinent medical literature. Two patients with history of HIV infection developed weight loss, tachycardia, tremor, and diarrhea after 30-48 months of treatment with HAART based on zidovudine, lamivudine, and atazanavir. Their CD4 T cells count was in normal range and viral load was undetectable. Physical examination showed diffuse thyroid enlargement. Thyrotropin was suppressed, free thyroxine was elevated, and anti-TPO antibodies were positive. Both showed clinical improvement with the use methimazole and atenolol. Graves’ disease may be a form of immune reconstitution syndrome following HAART. This form of autoimmune thyroid disease is related with the second phase of T-cell repopulation with naive autoreactive CD4 T cells clones. Physicians need to be vigilant in detecting thyrotoxicosis in patients who have immune reconstituted well on HAART, since early diagnosis and treatment alleviates symptoms and may reduce long-term morbidity of Graves’ disease.

Keywords : Graves’ disease; hyperthyroidism; immune reconstitution syndrome.

        · abstract in Spanish     · text in Spanish     · Spanish ( pdf )

 

Creative Commons License All the contents of this journal, except where otherwise noted, is licensed under a Creative Commons Attribution License